S
Sunshine Biopharma, Inc. (SBFM)
NCM – Real Time Price. Currency in USD
1.02
+0.01 (0.99%)
At close: Mar 27, 2026, 4:00 PM EDT
1.03
+0.01 (0.98%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
1.02
+0.01 (0.99%)
At close: Mar 27, 2026, 4:00 PM EDT
1.03
+0.01 (0.98%)
After-hours: Mar 27, 2026, 7:59 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.20 | 2.52 | 10 | |
| Quick ratio | 2.09 | 1.78 | 10 | |
| Debt to Equity | 0.04 | -0.80 | 9.0 | |
| Debt to Assets | 0.03 | 0.73 | 9.0 | |
| Interest coverage | N/A | -13.90 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 228K | 4M | 24M | 35M | 37M |
| Gross Profit | 98K | 2M | 8M | 10M | 12M |
| Operating Income | -2M | -9M | -5M | -6M | -5M |
| Net Income | -12M | -27M | -5M | -5M | -6M |
| EBITDA | -2M | -9M | -5M | -6M | -5M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 4.23 | 73.27 | 7.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | 8.19 | 86.2 | 8.0 |
| Next year | 32.52 | 68.32 | 10 |
| Weighted average score | 6.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 0.07 | 50.09 | 51.28 | 48.67 | 8.0 |
| Y/Y | 11.64 | 26.21 | 79.79 | 60.82 | 9.3 |
| 3y average | 767.19 | -15.26 | N/A | -108.09 | 3.3 |
| 5y average | 551.91 | -110.04 | N/A | -106.92 | 3.3 |
| Weighted average score | 6.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $9.3M significantly exceed its total debt $854.8K, ensuring strong financial flexibility
Total current assets $28.0M exceed Total current liabilities $6.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (-0.8), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$735.8K limits the company's ability to reinvest or pay down debt